Omega-3 fatty acids EPA+DHA (general-population cancer chemoprevention research context)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-OMEGA-3-FATTY-ACIDS-CHEMOPREVENTION |
|---|---|
| Type | Drug |
| Aliases | Fish oil EPA+DHALovaza (EPA+DHA ethyl esters)Marine omega-3OmacorOmega-3 fatty acids EPA+DHA (cancer chemoprevention)many OTC fish-oil supplementsn-3 PUFAОмега-3 жирні кислоти EPA+DHA (хіміопрофілактика раку — дослідницький контекст) |
| Status | reviewed 2026-05-18 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-USPSTF-CRC-2021 SRC-WCRF-AICR-CUP-2018 |
Drug Facts
| Class | Omega-3 polyunsaturated fatty acids (marine origin) — combination EPA + DHA |
|---|---|
| Mechanism | EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) are long- chain n-3 polyunsaturated fatty acids that compete with arachidonic acid as substrates for cyclooxygenase and lipoxygenase, shifting eicosanoid production toward less inflammatory 3-series prostaglandins and 5-series leukotrienes; they also modulate membrane fluidity, PPAR-α/γ signaling, and resolvin / protectin lipid mediators that resolve inflammation. Cancer-prevention rationale: lower inflammation, reduced PGE2-driven epithelial proliferation, and altered membrane composition. Distinct from DRUG-OMEGA-3-EPA (FAP-specific high-dose EPA monotherapy entity); this entity captures general-population EPA+DHA chemoprevention. VITAL omega-3 arm (Manson NEJM 2019, NCT01169259): 1 g/day EPA+DHA (840 mg EPA+DHA, Omacor) did NOT reduce total invasive cancer or cancer mortality vs. placebo over ~5 years. |
| Typical dosing | Cancer-prevention research context (VITAL protocol): 1 g/day EPA+DHA ethyl-ester capsule (Omacor; ~460 mg EPA + 380 mg DHA). Most epidemiologic-based recommendations: 1-2 g/day total EPA+DHA from fish or supplements. Hypertriglyceridemia (on-label): 4 g/day. Take with food. Some advocate split BID dosing for tolerability. No specific cancer-prevention dose has been validated outside VITAL (null result). |
| Ukraine registered | True |
| NSZU reimbursed | False |
| Ukraine last verified | 2026-05-18 |
Notes
STUB — v0.2 chemoprevention-workstream authoring; pending two-Clinical- Co-Lead signoff per CHARTER §6.1 dev-mode. RESEARCH-ONLY chemoprevention. Distinct from DRUG-OMEGA-3-EPA (which captures purified high-dose EPA monotherapy for FAP duodenal polyposis). VITAL primary outcome NULL: 1 g/day EPA+DHA over ~5 years did not reduce total invasive cancer (HR 1.03) or cancer mortality. seAFOod (UK polyp prevention with EPA + aspirin) — primary endpoint negative. Some subgroup signals (African American participants in VITAL had nominally lower CRC incidence — exploratory). Cardiac-rhythm signal: AF risk modestly increased at higher doses. USPSTF / WCRF: omega-3 supplementation NOT recommended for cancer prevention (insufficient or null evidence). Engine should NOT auto-recommend for cancer prevention; may be reasonable for hypertriglyceridemia (on-label) or general dietary supplementation per patient preference.
Used By
No reverse references found in the YAML corpus.